Global Neuroendocrine Cancer Market - 2022-2029

Global Neuroendocrine Cancer Market - 2022-2029

Market Overview

The Neuroendocrine Cancer Market size was valued at USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 10.6% during the forecast period (2022-2029).

Neuroendocrine tumors are tumors that start in specialized neuroendocrine cells. Nerve cells and hormone-producing cells share characteristics with neuroendocrine cells.

Market Dynamics

The increasing research and development and the growing prevalence of neuroendocrine cancer are expected to drive market growth.

Immunotherapy, also known as biologic therapy, is a type of treatment that aims to increase the body's natural defenses to combat a tumor. Researchers have tested new cancer vaccinations on NETs (Neuroendocrine Tumor Treatment). Another area of immunotherapy research is the development of medicines that block the protein PD-1. T cells, white blood cell that aids the body's immune system in fighting disease, have PD-1 on their surface. Because PD-1 prevents the immune system from eliminating tumor cells, blocking it permits it to remove the disease more effectively.

Atezolizumab (Tecentriq), a PD-L1 inhibitor, has been approved by the FDA for treating metastatic small cell lung cancer in conjunction with carboplatin and etoposide chemotherapy (both of which are available as generic medicines). Although lung NETs are a distinct disease, the efficacy of atezolizumab highlights the need for further research into immunotherapy for patients with lung NETs. Also being investigated is chimeric antigen receptor treatment (CAR T-cell therapy) in combination with antibody-drug conjugates, a targeted therapy. CAR T-cell treatment involves removing a patient's T cells, which are part of their immune system, and reprogramming them to target cancer cells in the patient.

The T cells are then reintroduced to the patient. Moreover, on August 13, 2021, Belzutifan (Welireg), a hypoxia-inducible factor inhibitor, was approved by the FDA for adult patients with von Hippel-Lindau disease who need treatment for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors but don't need surgery right away.

The side effects associated with neuroendocrine cancer treatment are expected to hamper the market.

Targeted therapy targets the tumor's unique genes, proteins, or tissue environment, all of which play a role in cancer growth and survival. This treatment inhibits tumor cell growth and spreads while limiting damage to healthy cells. The targets of all cancers are not the same. The US Food and Drug Administration (FDA) has approved Everolimus (Afinitor) for treating advanced NETs of the GI tract, lung, and pancreas.

This medicine targets the mTOR protein, which is essential for cell growth and survival. In some people, this medicine can help delay the growth of these tumors, but it seldom shrinks them. Some side effects include mouth sores, lowered blood counts, and exhaustion. Sunitinib (Sutent) is a targeted medication that inhibits the production of a protein known as VEGF. Angiogenesis, or the formation of new blood vessels, necessitates the presence of VEGF. The purpose of anti-angiogenesis medicines like sunitinib is to ""starve"" the tumor of nutrients given by blood vessels, which are required for it to develop and spread. The FDA has given it the approval to treat advanced pancreatic NETs. Diarrhea, nausea, vomiting, lethargy, and elevated blood pressure are common side effects of this medication.

In clinical studies, further targeted treatments for NETs are being investigated. Drugs that block the creation of new blood vessels or specific cancer cell survival pathways are among them.

Industry Analysis

The neuroendocrine Cancer market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain and regulatory analysis etc.

COVID-19 Impact Analysis

There have been particular concerns about the impact of the COVID-19 pandemic on specialized tumor services. Neuroendocrine tumor (NET) services are typically provided in a restricted number of centers and are highly specialized. Following COVID-19, the restoration of highly specialized NET services, as well as future service delivery and research funding, must take into account the extreme challenges faced during the pandemic. Hence, the neuroendocrine cancer market is expected to be impacted by covid-19.

Segment Analysis/B>

Targeted Therapy segment is expected to hold the largest market share in neuroendocrine cancer market

The targeted therapy segment accounted for the largest market share in 2021. Targeted medications differ from regular chemotherapy (chemo) drugs in their function. These medications are designed to target specific regions of cancer cells. They can be useful in situations when chemo isn't, and they frequently have distinct adverse effects than chemo. Pancreatic neuroendocrine tumors (NETs) are treated with targeted medications that prevent angiogenesis (the creation of new blood vessels that fuel malignancies) or critical proteins (called tyrosine kinases) in cancer cells that help them grow and survive.

Moreover, sunitinib inhibits the formation of new blood vessels by blocking multiple tyrosine kinases. It has been demonstrated to assist in the slowing of tumor growth. This medication is used once a day as a tablet. Everolimus inhibits mTOR, a protein that typically aids cell growth and division. It has been demonstrated to be effective in treating advanced pancreatic NETs. Everolimus is a tablet that needs to be taken once a day.HIF inhibitors, such as Belzutifan, are a type of medication. It inhibits a protein known as hypoxia-inducible factor 2 alpha (HIF-2a), which is implicated in cancer cell development and tumor blood vessel creation. This medication is given as pills once a day. Belzutifan is a drug that can be used to treat persons with von Hippel-Lindau disease (VHL) who have a pancreatic NET but don't need surgery immediately or quickly.

Geographical Analysis

North America region holds the largest market share in the global Neuroendocrine Cancer market

The increasing prevalence of neuroendocrine cancer and growing R&D are expected to drive market growth. In the United States, it is estimated that about 12,000 people are diagnosed with a NET each year, with around 175,000 people living with this diagnosis. The number of persons diagnosed with this tumor has been rising for years. Moreover, Cancer research has traditionally been a source of R&D investment. Aside from research foundations, governments in a number of nations have been involved in cancer research and funding. For example, in January 2021, the Neuroendocrine Tumor Research Foundation (NETRF) gave $2.62 million in grants to advanced research focusing on innovative therapeutics for neuroendocrine tumors. NETRF has spent $30 million on research over the last 15 years. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the neuroendocrine cancer market are Novartis AG, Pfizer Inc., Ipsen, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., Exelixis, Inc., Advanced Accelerator Applications, Argos Therapeutics Inc.

Amgen:

Overview:

Amgen is one of the world’s leading biotechnology companies. It is engaged in pharmaceutical product research, development, and manufacturing. Amgen is a values-based company deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. The company offers a wide range of products for treating the central nervous system, neurosciences, ophthalmology, cancer, medical aesthetics, plastic surgery, dermatology, liver disease, inflammation, metabolic syndromes, and fibrosis. Amgen has 40 manufacturing facilities and 27 R&D, and Amgen, Inc is a biotechnology company that engages in the discovery, development, manufacture and marketing of human therapeutics and marketing facilities across the world.

Product Portfolio:

DLL3 (Delta-like protein 3) is a protein that acts as an inhibitor. In the lungs, the Notch pathway is essential for neuroendocrine versus epithelial cell differentiation and control. DLL3 is found in the Golgi apparatus, where it suppresses Notch 1 signaling.

The global neuroendocrine cancer market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.